Zealand Pharma doses first patients testing its drug for congenital hyperinsulinism
Zealand Pharma has doesd its first patient in Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism, the company said Wednesday.
Pharmaceuticals, Biotechnology and Life Sciences
Zealand Pharma has doesd its first patient in Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism, the company said Wednesday.
Bexion’s Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer has exceeded expectations in screening and enrollment at their 4 trial sites.
FDA has granted Priority Review for Eli Lilly’s sBLA for Emgality (galcanezumab-gnlm) injection for the preventive treatment of episodic cluster headache in adults, the company said Tuesday in a press release.
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Telmisartan and Hydrochlorothiazide Tablets .
Novartis has had Cosentyx compared against Janssen’s IL-23 Stelara, and it showed superior improvements for psoriasis patients, it said in a statement Tuesday, noting that it was processed and transmitted by West Corporation.
BioPharmX Corporation has enrolled patients for its Phase 2b testing BPX-04, a new drug limited by U.S. law to investigational use, topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea.
Shield Therapeutics got positive results from the AEGIS-H2H clinical trial which compared Feraccru (ferric maltol) to Ferinject (ferric carboxymaltose (FCM)), as Feraccru has demonstrated it is non-inferior to IV iron therapy in treating iron deficiency anaemia.
Biogen said Monday it will buy Nightstar Therapeutics, a clinical-stage gene therapy company based in London, United Kingdom, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.
Verona Pharma is aiming to start second part of Phase 2 trial to test ensifentrine DPI formulation in patients with moderate-to-severe COPD over one week of twice-daily treatment, it said after announcing positive data from part one of the trial.
Auden Mckenzie and Waymade have breached UK and EU competition law by entering into anti-competitive agreements in relation to the supply of hydrocortisone tablets in the UK.